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http://dx.doi.org/10.1016/j.ccell.2015.07.004SUMMARYBiomarkers for predicting prognosis are critical to treating colorectal cancer (CRC) patients. We found that
CSN6, a subunit of COP9 signalosome, is overexpressed in CRC samples and that CSN6 overexpression
is correlated with poor patient survival. Mechanistic studies revealed that CSN6 is deregulated by epidermal
growth factor receptor (EGFR) signaling, in which ERK2 binds directly to CSN6 Leu163/Val165 and phosphor-
ylates CSN6 at Ser148. Furthermore, CSN6 regulated b-Trcp and stabilized b-catenin expression by blocking
the ubiquitin-proteasome pathway, thereby promoting CRC development. High CSN6 expression was
positively correlated with ERK2 activation and b-catenin overexpression in CRC samples, and inhibiting
CSN6 stability with cetuximab reduced colon cancer growth. Taken together, our study’s findings indicate
that the deregulation of b-catenin by ERK2-activated CSN6 is important for CRC development.INTRODUCTION
Colorectal cancer (CRC) is a leading cause of cancer mortality.
The primary treatment for CRC patients is surgery, and conven-
tional cytotoxic chemotherapy and/or targeted therapies are
routinely used to treat patients who are at high risk of developing
recurrent or metastatic disease (Laurent-Puig et al., 2009). The
molecular alterations in CRC have been studied extensively.
Specific molecular marker analyses (e.g., microsatellite insta-
bility, CpG island methylator phenotype, PIK3CA, RAS, and
BRAF mutations) are becoming routine clinical practice in deter-
mining CRC treatment (Cancer Genome Atlas Network, 2012;Significance
CSN6 is a biomarker that is elevated in colon cancer and leads
through EGFR/ERK signaling, has unprecedented biological a
thereby stabilizing b-catenin; this confirms CSN6’s role in pro
mechanism by which b-catenin is regulated through the EGFRKarapetis et al., 2008; Ogino et al., 2014; Walther et al., 2009).
For example, RAS and BRAF mutations have impact on the
clinical management of CRC (Amado et al., 2008; Bardelli and
Siena, 2010; Douillard et al., 2013; Pietrantonio et al., 2015).
However, a more detailed picture of the pathways deregulated
in CRC has yet to emerge. Defining these molecular alterations
can help guide treatment and improve clinical care (Siena
et al., 2009).
The COP9 signalosome (CSN) is a multiprotein complex
involved in protein degradation, transcriptional activation
(Seeger et al., 1998; Wei and Deng, 1999), signal transduction
(Chen et al., 2012; Xue et al., 2012; Zhang et al., 2008), andto worse recurrence-free survival. CSN6, which is regulated
ctivity in downregulating b-Trcp, an E3 ligase for b-catenin,
moting colon cancer development. Our findings elucidate a
-ERK2-CSN6 axis during CRC development.
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Figure 1. CSN6 Is Overexpressed and Associated with Poor Survival in CRC
(A) Twenty CRC samples were collected and subjected to gene expression microarray. The expression of all subunits of COP9 signalosome is presented as a
heat map.
(B) Relative expression of CSN6 in 20 CRC patients. The bounds of the boxes denote interquartile ranges; solid lines within the boxes denote medians, and
whiskers denote the 5th and 95th percentiles. **p < 0.01.
(C) CSN6 gene mRNA levels were assessed from TCGA. Amplification of the CSN6 gene was associated with advanced disease stage. The bounds of the boxes
denote interquartile ranges; solid lines within the boxes denote medians, and whiskers denote the 5th and 95th percentiles. **p < 0.01; ***p < 0.001.
(D) Waterfall plot of relative CSN6 mRNA levels of 33 paired samples of CRC and normal tissue measured using qRT-PCR.
(E) Representative IHC staining for CSN6 in human colon cancer (right) and adjacent normal colon tissue (left). CSN6 expression in 81 paired samples of CRC
and normal colon tissue was assessed by immunohistochemistry. Scale bars represent 50 mm.
(legend continued on next page)
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tumorigenesis (Chen et al., 2014; Richardson and Zundel, 2005;
Zhao et al., 2011, 2013, 2014). However, the detailed biological
functions of the CSN’s subunits have not been well character-
ized. Several studies have indicated that mammalian CSN sub-
units are involved in developmental processes; examples include
targeted disruptions of mammalian Csn2, Csn3, Csn5, and Csn8
that resulted in defective embryo development (Lykke-Andersen
et al., 2003; Menon et al., 2007; Tomoda et al., 2004; Yan et al.,
2003). The role of CSN subunits in cancer biology is emerging
(Lee et al., 2011). Our own work has shed some light on the func-
tion of the CSN6 subunit specifically. In a previous study, we per-
formed targeted disruption of the Csn6 gene in mice and found
that Csn6/ mice developed until 7.5 days post-coitus but
not beyond this time (Zhao et al., 2011). In that same study,
Csn6+/ mouse tumor experiments showed that Csn6 haplo-
insufficiency helps impede the development of cancer (Zhao
et al., 2011), suggesting that CSN6 signaling regulation is critical
for tumor development. However, the mechanism and biological
consequence of CSN6 overexpression in cancer remain unclear.
In this study, we characterized the mechanism of CSN6 overex-
pression during the CRC tumorigenesis.
RESULTS
CSN6 Is Overexpressed in and Is a Biomarker for Colon
Cancer
To identify potential gene deregulation correlated with the out-
comes of CRC patients, we analyzed the gene expression pro-
files of snap-frozen CRC tissues resected from 20 CRC patients.
A comparison of gene expression levels changed in CRC pa-
tients with recurrence-free survival (RFS) %3 years and those
with RFS >3 years indicated that CSN6 is one of the top genes
deregulated in CRC (Figure S1A; Table S1).
Microarray analysis showed that CSN6 expression in CRC
samples frompatients with anRFS duration%3 yearswas signif-
icantly higher than that in CRC samples from patients with an
RFS duration >3 years (p = 0.004) (Figures 1A and 1B). Using
the BioGPS Gene Expression Atlas, we found that CSN6, but
not CSN5, was highly expressed in colon cancer (Figures S1B
and S1C). Furthermore, an analysis of mRNA expression data
from The Cancer Genome Atlas (TCGA) revealed that the level
of CSN6 expression was higher in cancer tissue than in normal
tissue and was positively correlated with advanced disease
(Figure 1C), whereas the level of CSN5 expression in normal
colon tissue did not differ significantly from that in CRC
(Figure S1D). Validating these findings, quantitative RR-PCR
(qRT-PCR) analysis of CSN6 expression in 33 paired samples
of colon cancer tissue and adjacent normal mucosa revealed
that CSN6 expression in cancer tissue was significantly higher
than that in normal tissue (Figure 1D). Finally, an immunohisto-
chemistry tissue microarray revealed that CSN6 expression in
CRC was higher than that in normal tissue in 67 of 81 (82.7%)
paired samples (Figures 1E and 1F). Western blot analysis of
endogenous CSN6 expression in one colon cell line (HCEC)(F) A box plot illustrates the relative expression of CSN6 in 81 paired samples of
represent the interquartile range, and the whiskers represent the 5th and 95th pe
(G and H) Kaplan-Meier survival curves of overall survival duration based on CS
receiver operating characteristic curve was used to define the cutoff, and log-ranand four CRC cell lines (DLD-1, HCT116, SW480, and AKP)
revealed that CSN6 is overexpressed in the CRC cell lines but
not in the normal colon cells (Figure S1E). Therefore, CSN6 can
be identified as a biomarker overexpressed in human colon
cancer samples.
CSN6Overexpression Is Correlated with Poor Prognosis
in CRC Patients
Because CSN6 expression is significantly increased in CRC, we
sought to determine whether CSN6 expression is associated
with the prognosis and/or clinical characteristics of CRC pa-
tients. The testing cohort included paired samples of normal
colon and CRC from 81 patients. The validation cohort included
CRC samples from 305 patients. The CSN6 expression level
was determined using immunohistochemistry tissue microarray.
High CSN6 expression was positively correlated with older
patients in the testing cohort and with advanced clinical stage
in the validation cohort (p < 0.05; Table 1). Kaplan-Meier analysis
showed that high levels of CSN6 expression were correlated
with poor overall survival in both cohorts (Figures 1G and 1H).
Further, multivariate Cox regression analysis revealed CSN6
expression to be an independent prognostic factor for poor
survival (Table 2). In another analysis, Kaplan-Meier estimate
shows significantly (p = 0.006) shorter overall survival in patients
with high CSN6 gene expression in the colorectal adenocarci-
noma (Cancer Genome Atlas Network, 2012) (Figure S1F).
EGF-ERK Signaling Increases CSN6 Stability
We performed Gene Set Enrichment Analysis (GSEA) to identify
association between expression of CSN6 and signaling path-
ways in two sets of colon cancer GSE14333 (n = 290) and
GSE2109 (n = 373). Result showed that gene sets of epidermal
growth factor receptor (EGFR) and KRAS were enriched in
samples with high expression of CSN6 (Figures S2A and S2B).
Because EGFR signaling is highly activated in colon cancer,
we sought to determine whether EGFR activation regulates
CSN6 expression. Immunoblot analysis showed that EGF treat-
ment increased the steady-state expression of CSN6 in DLD-1
colon cancer cells, whereas inhibition of MEK/ERK by the
MEK1 inhibitor PD98059 diminished the EGF-induced increase
of CSN6 expression (Figure 2A). CSN6 mRNA levels did not
increase significantly in response to EGF (Figure S2C), suggest-
ing that EGF regulates CSN6 posttranslationally. In addition, the
expression of a constitutively active MEK1 (MEK1CA) increased
CSN6 expression in DLD-1 cells (Figure S2D).
A coimmunoprecipitation assay revealed that ERK1/2 binds to
CSN6 (Figure 2B). Furthermore, we found that EGF treatment
or ERK2 activation decreases the ubiquitination level of CSN6
(Figures 2C and 2D). Congruently, PD98059 increased the
turnover rate of CSN6 in the presence of the de novo protein syn-
thesis inhibitor cycloheximide (Figure 2E), whereas EGF, which
induced ERK activation, reduced CSN6 turnover (Figure 2F).
Taken together, these results indicate that EGFR-ERK signaling
helps to stabilize CSN6.normal tissue and CRC. The horizontal lines represent the medians; the boxes
rcentiles. ***p < 0.001, Student’s t test.
N6 expression in the CRC tissues of the testing and validation cohorts. The
k analysis was used to test for significance. See also Figure S1 and Table S1.
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Table 1. Correlation between Expression of CSN6 and Clinicopathological Features of CRC Patients
Variable
Testing Cohort Validation Cohort
Low CSN6 High CSN6 p Valuea Low CSN6 High CSN6 p Valuea
Gender 0.350 0.568
Male 22 (71.0) 30 (60.0) 78 (54.5) 83 (51.2)
Female 9 (29.0) 20 (40.0) 65 (45.5) 79 (48.8)
Median age 0.010 0.301
<59 years 19 (61.3) 15 (30.0) 72 (50.3) 71 (43.8)
R59 years 12 (38.7) 35 (70.0) 71 (49.7) 91 (56.2)
Histological grade 0.860 0.588
G1 4 (12.9) 7 (14.0) 8 (5.6) 13 (8.0)
G2 21 (67.7) 31 (62.0) 115 (80.4) 123 (75.9)
G3 6 (19.4) 12 (24.0) 20 (14.0) 26 (16.0)
pT status 0.509 0.161
T1 1 (3.2) 2 (4.0) 7 (4.9) 2 (1.2)
T2 4 (12.9) 7 (14.0) 21 (14.7) 17 (10.5)
T3 23 (74.2) 30 (60.0) 112 (78.3) 140 (86.4)
T4 3 (9.7) 11 (22.0) 3 (2.1) 3 (1.9)
pN status 1.000 0.289
N0 15 (48.4) 24 (48.0) 85 (59.4) 106 (65.4)
N1 16 (51.6) 26 (52.0) 58 (40.6) 56 (34.6)
pM status 0.518 0.038
M0 28 (90.3) 42 (84.0) 134 (93.7) 140 (86.4)
M1 3 (9.7) 8 (16.0) 9 (6.3) 22 (13.6)
Clinical stage 0.819 0.028
I 4 (12.9) 7 (14.0) 21 (14.7) 13 (8.0)
II 11 (35.5) 14 (28.0) 59 (41.3) 78 (48.1)
III 13 (41.9) 21 (42.0) 54 (37.8) 49 (30.2)
IV 3 (9.7) 8 (16.0) 9 (6.3) 22 (13.6)
Chemotherapy (%) 1.000 0.795
No 17 (54.8) 27 (54.0) 107 (74.8) 119 (73.5)
Yes 14 (45.2) 23 (46.0) 36 (25.2) 43 (26.5)
All data are the number of patients (%).
ap values were calculated in SPSS16.0 using a chi-square test. p values < 0.05 were considered to indicate statistical significance.Model of CSN6-ERK Interaction
ERK cascades are critical to the regulation of signals initiated
by growth factors and other stimuli, including EGF (Bardwell,
2006). MAP kinases (MAPKs) bind to their substrates through a
docking groove comprised of an acidic common docking (CD)
domain and glutamic acid-aspartic acid pocket (Lu and Xu,
2006). Immunoblotting of the immunoprecipitated myc-ERK2
proteins with an anti-CSN6 antibody showed that compared
with WT ERK2, ERK2 with mutations in the CD domain (D318/
321N) or glutamic acid-aspartic acid pocket (T159/160E) had
reduced binding to endogenous CSN6 (Figure 2G). Also, many
MAPK substrates contain dockingmotifs (D-sites), which consist
of a cluster of basic residues, a short spacer, and a hydrophobic
(4)-X-hydrophobic (4) motif (K/R -X1–6 -4-X -4) (Bardwell, 2006;
Bardwell et al., 2009; Whisenant et al., 2010). An analysis of the
CSN6 amino acid sequence identified the consensus D-site as
159-KHTDLPVS-166 (Figures 2H and S2E). When its D-site
was mutated to alanine (LV/AA), CSN6 lost its ability to bind186 Cancer Cell 28, 183–197, August 10, 2015 ª2015 Elsevier Inc.to MAPK (Figure 2I), suggesting that the ERK docking groove
binds to a D site at L163/V165 in CSN6.
To gain insight into the structural basis of CSN6’s recognition
byMAPK, we used HADDOCK to generate amodel of the CSN6-
MAPK complex (de Vries et al., 2010; Kelley and Sternberg,
2009). Structure modeling using CSN6’s structure (Zhang
et al., 2012) and the known MAPK docking groove (Tanoue
et al., 2000) (CD groove, residues E81, D318, and D321) indi-
cated close contact between the loop11 and a4 helix of CSN6
(residues 159–165,D-site) andMAPKdocking groove (Figure 2J).
Basically, MAPK docking grooves are adjacent to each other,
and their side chains are exposed at the surface of MAPK. These
negatively charged residues are critical to MAPK’s interaction
with the D-sites of its substrates (Tanoue et al., 2000). The
D-site of CSN6 (loop11 and a 4 helix of CSN6, residues 159–
165) docks to the major docking groove of MAPK (Figure 2J).
The highly positively charged residues in CSN6’s D-site bind
to the negatively charged residues in MAPK’s CD groove. The
Table 2. Univariate andMultivariate Analysis of Different Prognostic Parameters for CRCPatients in the TestingCohort and Validation
Cohort
Variable
Univariate Analysis Multivariate Analysis
HR (95% CI)a p Valueb HR (95% CI)a p Valueb
Testing cohort (n = 81)
Gender (male versus female) 1.4 (0.7–2.9) 0.361 0.6 (0.2.7) 0.384
Age (<59 years versusR59 years) 1.8 (0.8–4.0) 0.133 1.9 (0.8–4.5) 0.148
Chemotherapy (no versus yes) 1.7 (0.8–3.4) 0.167 1.7 (0.8.8) 0.188
Histological grade (G1 or G2 versus G3) 2.1 (1.0–4.4) 0.060 1.7 (0.7–4.0) 0.250
pT status (T1 or T2 versus T3 or T4) 6.1 (0.8–44.8) 0.076 2.5 (0.3–20.0) 0.391
pN status (N0 versus N1) 3.0 (1.4–6.8) 0.007 2.6 (1.1–6.2) 0.034
pM status (M0 versus M1) 6.8 (3.1–14.9) <0.001 8.0 (3.0–21.6) <0.001
CSN6 expression (low versus high) 3.4 (1.3–9.0) 0.012 3.7 (1.3–10.6) 0.015
Validation cohort (n = 305)
Gender (male versus female) 1.2 (0.8–1.8) 0.466 1.6 (1.0–2.4) 0.048
Age (<59 years versusR59 years) 1.4 (0.9–2.1) 0.152 1.4 (0.9–2.2) 0.100
Chemotherapy (no versus yes) 1.1 (0.65–1.7) 0.837 1.1 (0.6–1.8) 0.795
Histological grade (G1 or G2 versus G3) 1.7 (1.0–2.8) 0.048 1.6 (0.9–2.7) 0.096
pT status (T1 or T2 versus T3 or T4) 1.5 (0.8–3.0) 0.208 0.9 (0.5–1.8) 0.852
pN status (N0 versus N1) 1.7 (1.1–2.7) 0.010 2.2 (1.5–3.5) <0.001
pM status (M0 versus M1) 7.2 (4.5–11.6) <0.001 7.9 (4.6–13.4) <0.001
CSN6 expression (low versus high) 2.7 (1.7–4.5) <0.001 2.4 (1.5–4.1) 0.001
aHazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using univariate or multivariate Cox proportional hazards regression in
SPSS 16.
bp values were calculated using univariate or multivariate Cox proportional hazards regression in SPSS 16.0. p values < 0.05 were considered to
indicate statistical significance.docking model indicates that the electrostatic interactions are
made between the charged residues K97, K102, H160, and
K159 of CSN6 and the charged residues E81, D162, D318, and
D321 of MAPK (Figure 2K). The hydrophobic interactions occur
between the residues Y106, M157, T158, T161, and V165 of
CSN6 and the residues Y128, T159, T160, and C161 of MAPK
(Figure 2K). The model reveals that CSN6 D-site interacts with
the MAPK docking groove.
The EGF-ERK2 Axis Phosphorylates CSN6 on S148
and Enhances CSN6 Stabilization
Sequence analysis of CSN6 using the NetPhos algorithm (http://
www.cbs.dtu.dk/services/NetPhos) and GPS2.1 (http://Gps.
Biocuckoo.org) revealed that CSN6 contains an ERK consensus
phosphorylation motif (Ser-Pro) at the S148 residues (Figure 3A).
Treatment with calf intestinal alkaline phosphatase (CIP) reduced
the EGF-induced steady-state expression of CSN6, indicating
that CSN6 phosphorylation is required in this process (Figure 3B)
and presumably acts through ERK.
To determine the way in which the EGF-induced stabilization
of CSN6 involves phosphorylation, we constructed S148A and
S148D phosphorylation site mutants of CSN6 and assessed
their steady-state expression in the presence of EGF. The
CSN6 S148A mutant did not respond to EGF-induced upregu-
lation, whereas the WT CSN6 was upregulated by EGF. Even
in the absence of EGF, the phosphorylation-mimetic CSN6
S148D mutant had a higher level of expression than the WT
CSN6 or the CSN6 S148A mutant did (Figure 3C).To confirm the existence of an ERK-specific phosphorylation
site in CSN6 in vivo, we used an anti-phospho-serine antibody
to detect the increase of serine-phosphorylated CSN6 in EGF-
treated cells (Figure 3D). MEK1 inhibition with PD98059 treat-
ment abolished the serine phosphorylation of CSN6 (Figure 3D).
Compared with WT CSN6, the CSN6 S148A mutant had signifi-
cantly lower serine phosphorylation levels in vivo (Figure 3D).
Accordingly, CSN6 S148A was resistant to phosphorylation by
recombinant ERK, whereas WT CSN6 was highly phosphory-
lated by ERK, in an in vitro kinase assay (Figure 3E). We then
found that the CSN6 S148A mutant had a faster turnover rate
than WT CSN6 did. As expected, the turnover rate of the CSN6
S148D mutant was slower than that of WT CSN6 (Figure 3F).
We assessed the ubiquitination of CSN6 in the presence of
EGF and found that EGF reduced the ubiquitination level of WT
CSN6 but not that of the CSN6 S148A mutant (Figure 3G).
Even in the absence of EGF, the phosphorylation-mimetic
CSN6 S148D mutant had a lower ubiquitination level than WT
CSN6 or the CSN6 S148A mutant did (Figure 3G). Together,
these results indicate that EGF/ERK mediated CSN6 phosphor-
ylation and diminished CSN6 ubiquitination and turnover.
To determine the biological significance of CSN6 phos-
phorylation, we transiently transfected DLD-1 cells with WT
CSN6 or CSN6S 148A plasmid and measured their growth.
A 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay demonstrated that cells transfected with WT
CSN6 had significant growth, whereas cells transfected with
CSN6 S148A lost growth capability (Figure 3H). Also, WTCancer Cell 28, 183–197, August 10, 2015 ª2015 Elsevier Inc. 187
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Figure 2. The EGF-ERK Axis Regulates CSN6 Stability
(A) DLD-1 cells were treated with or without PD98059 (20 mM) for 1 hr and then treated with EGF (100 ng/ml) for 30 min. Equal amounts of cell lysates were
immunoblotted with the indicated antibodies.
(B) DLD-1 cell lysates were immunoprecipitated with an anti-CSN6 antibody and immunoblotted with the indicated antibodies.
(C) DLD-1 cells were treated with or without EGF (100 ng/ml). MG132 was added to the cells 6 hr before they were harvested with a guanidine-HCl-containing
buffer. The cell lysates were pulled down with nickel beads and immunoblotted with an anti-CSN6 antibody.
(D) DLD-1 cells were transfected with vectors expressing the indicated myc-tagged ERK and MEK1CA proteins. MG132 was added to the cells 6 hr before
they were harvested with a guanidine-HCl-containing buffer. The cell lysates were pulled down with nickel beads and immunoblotted with an anti-CSN6
antibody.
(legend continued on next page)
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CSN6 increased cell migration and invasion in a wound-healing
assay (p < 0.001, Figure 3I) and in Transwell migration/invasion
assays (Figures 3J and 3K), whereas CSN6 S148A lost such
capability, demonstrating that the CSN6-promoted migration
and invasion of colon cancer cells requires a phosphorylation
event.
CSN6 Positively Regulates b-Catenin Protein Stability
and Facilitates the Transcriptional Activity of b-Catenin
Because b-catenin plays an important role in CRC and can be
upregulated by EGF activation (Yang et al., 2011), we assessed
the expression of b-catenin and CSN6 under the condition of
EGF-ERK activation to further investigate the role of EGF-medi-
ated CSN6 phosphorylation/stabilization in regulating tumorige-
nicity. CSN6 and b-catenin expression were both upregulated in
DLD-1 and SW480 colon cancer cell lines after EGF treatment
(Figure 4A). CSN6 increased the steady-state expression of
b-catenin in a dose-dependent manner while downregulating
b-Trcp (Figure 4B). In line with this finding, western blotting
revealed that knockdown of CSN6 by shRNA decreased
the expression of b-catenin and increased the expression of
b-Trcp (Figure 4C).
The CSN6 knockdown-mediated b-catenin destabilization
translated into b-catenin’s reduced transcriptional activity, as
evidenced by qRT-PCR findings showing diminished expression
of b-catenin target genes, including myc, cyclin D, and vascular
endothelial growth factor (Figure 4D). Overexpression of CSN6
could increase the expression of b-catenin target genes (Fig-
ure S3A). The TOP-FLASH TCF/LEF-1 luciferase reporter gene
analyses showed that Flag-CSN6 significantly increased b-cate-
nin transactivation, but the activity of Flag-CSN6-S148A was
compromised (Figure 4E). Thus, CSN6 is involved in the b-cate-
nin pathway.
CSN6 Increases b-Catenin Expression by Hindering
the Ubiquitin-Mediated Degradation of b-Catenin
Because the stability of b-catenin is regulated by b-Trcp-medi-
ated ubiquitination/degradation (Liu et al., 1999; Winston et al.,
1999), we hypothesized that CSN6 negatively impacts the
b-Trcp protein to stabilize b-catenin. We found that CSN6 asso-
ciated with b-Trcp in vivo (Figure 4F), suggesting that CSN6
interacts with F-box protein b-Trcp and regulates it, thereby
stabilizing b-catenin.
qRT-PCR analysis revealed that the mRNA levels of b-Trcp
and b-catenin were not affected by CSN6 overexpression (Fig-(E) DLD-1 cells were treatedwith PD98059 (10 mM) and then treatedwith cyclohex
with the indicated antibodies.
(F) DLD-1 cells were starved overnight, treated with EGF (100 ng/ml), and th
immunoblotted with the indicated antibodies.
(G) Equal amounts of cell lysates from DLD-1 cells transfected with myc-ERK2
precipitated with an anti-CSN6 antibody and then immunoblotted with the indica
(H) The consensus sequence for the ERK2 substrate binding sites is highlight
comparison.
(I) Equal amounts of cell lysates from DLD-1 cells transfected withWT Flag-CSN6
antibody and immunoblotted with indicated antibodies.
(J) Structural model of the CSN6-ERK2 complex. The loop11 and a4 helix of CS
(K) The best complex HADDOCK (High Ambiguity Driven DOCKing) model displa
residues involved in the interface between CSN6 and ERK2 are indicated.
See also Figure S2.ure S3B), and western blotting revealed that CSN6-mediated
b-Trcp downregulation could be rescued by the proteasome
inhibitor MG132 (Figure 4G). These results suggest that CSN6
regulates b-Trcp and b-catenin at the posttranscriptional level.
CSN6 overexpression reduced the turnover rate of b-catenin
and increased the turnover rate of b-Trcp (Figure 4H). Further-
more, CSN6 increased the ubiquitination level of b-Trcp and
reduced the ubiquitination level of b-catenin (Figure 4I). Signifi-
cantly, we searched the Oncomine database for the expression
profiles of CSN6 and b-catenin target genes and found that
transcriptomic analysis of 373 colon cancer samples showed a
positive correlation between CSN6 expression and the expres-
sion of b-catenin target genes such as MYC, MET, and JUN
(Figures 4J and S3C).
The EGF-ERK-CSN6-b-Catenin Axis Promotes Cell
Proliferation and Tumor Growth
The EGF/ERK pathway is often deregulated in CRC, and the
monoclonal antibody cetuximab, an EGFR inhibitor, is used
clinically to correct this deregulation (Allegra et al., 2009; Prewett
et al., 2002). To investigate the role of the EGF-ERK-CSN6-
b-catenin axis in colon cancer tumorigenesis, we injected
DLD-1 cells into athymic nude mice. Treatment with cetuximab
inhibited tumor growth (Figures 5A and 5B) led to reduced
ERK1/2 phosphorylation and CSN6 expression in tumors (Fig-
ure 5C). qRT-PCR analysis showed that b-catenin target genes
were alsodownregulated after cetuximab treatment (FigureS4A).
Furthermore, we subcutaneously injected AKP colon cancer
cells and CSN6-depleted AKP colon cancer cells into athymic
nude mice. In the xenografted colon cancer samples, CSN6
depletion inhibited tumor growth by increasing b-Trcp while
downregulating b-catenin (Figures 5D–5F and S4B). Immunohis-
tochemical staining revealed that the expressions of CSN6 and
b-cateninwere decreased in shCSN6 tumor samples (Figure 5G).
b-catenin target genes in tumor samples were also downregu-
lated after CSN6 knockdown (Figure 5H).
To determine the clinical relevance, we subjected a tissue
microarray containing 305 human CRC specimens to immuno-
histochemical staining for p-ERK, CSN6, and b-catenin (Fig-
ure 5I). The CRC samples had high CSN6 expression, which
correlated with high ERK activation and high b-catenin expres-
sion (representative case 1). Accordingly, CRC samples with
lowCSN6 expression had low b-catenin expression and reduced
ERK activation (representative case 2). The p-ERK, CSN6, and
b-catenin expression levels were correlated with each otherimide (CHX; 100 mg/ml) for the indicated times. Cell lysates were immunoblotted
en treated with CHX (100 mg/ml) for the indicated times. Cell lysates were
, myc-ERK2-D318/321N (DN), or myc-ERK2-T159/160E (TE) were immuno-
ted antibodies.
ed. Sequences for CSN6 and other known ERK2 substrates are shown for
or Flag-CSN6 L163A/V165A (LVAA) were immunoprecipitated with an anti-Flag
N6 (residues 159–165, D-motif) fit into the major docking groove of ERK2.
ys a ribbon presentation of the CSN6-ERK2 complex structure. The interacting
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Figure 3. ERK2 Phosphorylates CSN6 S148
(A) ERK consensus phosphorylation motif of CSN6 (serine 148).
(B) The lysates from DLD-1 cells that were serum starved overnight and then stimulated with EGF for 1 hr were treated with calf intestinal phosphatase (CIP) and
subjected to immunoblotting.
(C) Cell lysates from DLD-1 cells expressing Flag-tagged WT CSN6, CSN6 S148A, or CSN6 S148D that had been starved overnight and then treated with or
without EGF (100 ng/ml) for 1 hr were subjected to immunoblotting.
(D) Flag-CSN6 was immunoprecipitated with an anti-Flag antibody from DLD-1 cells that had been pretreated with or without PD98059 for 1 hr and then treated
with EGF (100 ng/ml) for 30 min. Cell lysates were subjected to immunoblotting with an anti-phosphoserine antibody.
(legend continued on next page)
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(Table S2). These results strongly suggest that the p-ERK-CSN6-
b-catenin axis is deregulated during the development of human
CRC (Figure 5J).
DISCUSSION
In the present study, we found that CSN6 is a prognosis-asso-
ciated marker that is deregulated in colon cancer. CSN6
expression is elevated in colon cancer and leads to worse
RFS, suggesting that abnormal CSN6 expression causes treat-
ment resistance. In two cohorts of colon cancer patients, high
levels of CSN6 expression resulted in poor overall survival,
indicating that CSN6 has a critical role in colon cancer develop-
ment. CSN6 is a critical ubiquitination regulator involved in cell
cycle regulation (Choi et al., 2011; Xue et al., 2012) and p53
signaling pathway (Zhao et al., 2011), but its role in colon cancer
remains unclear. Noticeably, CSN6 is the major CSN subunit
highly deregulated in colon cancer, while CSN5, another sub-
unit frequently deregulated in cancer (Tomoda et al., 1999;
Zhao et al., 2014), is not particularly overexpressed in colon
cancer. In particular, we found that CSN6 has unprecedented
biological activity in downregulating b-Trcp, thereby stabilizing
b-catenin; this confirms CSN6’s role in promoting colon cancer
development by influencing a major molecular defect in the
disease.
ERK kinases bind to their substrates through a docking
groove, and these substrates usually contain a D-site that inter-
acts with ERK. In the present study, replacing some conserved
residues on the D-site compromised CSN6’s capacity to interact
with ERK, suggesting that these residues are involved in ERK-
CSN6 protein-protein interaction. This interaction leads to a
phosphorylation event. Our data show that S148 of CSN6 has
an ERK phosphorylation site. This site is located in the end
portion of CSN6’s MPN (Mpr1p and Pad1p N-terminal) domain,
which is found in the N terminus of yeastMpr1 and Pad1 proteins
(Penney et al., 1998; Rinaldi et al., 1995; Wei and Deng, 1999).
Although the biological function of the MPN domain remains
not well determined, the domain consists of polar residues that
resemble the active site residues of metalloproteases (Maytal-
Kivity et al., 2002) and is involved in a proteasome-associated
deneddylation activity (Lyapina et al., 2001). Whether this
phosphorylation event participates in any activity of the MPN
domain is unknown; regardless, this phosphorylation is critical
to maintaining the stability of CSN6. We previously showed
that S60 of CSN6 has an Akt phosphorylation site (Xue et al.,
2012) and that Akt increases the steady-state expression of
CSN6 (Xue et al., 2012). Together, these results demonstrated(E) In vitro kinase assays were conducted by incubating recombinant active ERK
subjected to immunoblotting with an anti-phosphoserine antibody.
(F) DLD-1 cells were transfected with the indicated plasmids and treated with CH
indicated antibodies. The density of Flag-CSN6 was measured, and the integrate
graphically.
(G) DLD-1 cells were transfected with Flag-CSN6(WT), Flag-CSN6(S148A), or F
the cells 6 hr before they were harvested with guanidine-HCl-containing buffer. T
anti-Flag antibody.
(H) DLD-1 cells were transfected with the indicated plasmids. Cell proliferation r
density of 570 nm. Data are means ± SD.
(I–K) DLD-1 cells were transfected with Flag-CSN6(WT), Flag-CSN6(S148A), a
migration assay, and invasion assay. The scale bar represents 200 mm. Data repthat CSN6 is regulated by two major signaling pathways (i.e.,
the ERK and Akt signaling pathways).
Our studies also showed that CSN6 can function in connection
with b-Trcp in a circuit, resulting in the negative regulation of
b-catenin protein. We found that CSN6 also associates with
b-Trcp and facilitates its degradation. The steady-state protein
level of the F-box protein b-Trcp is important in determining
the ubiquitin ligase activity of the whole SCFb-Trcp. Cullin-RING
ligase (CRL) substrate adaptors, such as F-box proteins, tend
to have autocatalytic degradation in vivo (Wee et al., 2005;
Zhou et al., 2003). Thus, keeping the F-box proteins stable has
a positive impact on the CRL, thereby facilitating the degradation
of CRL targets. Strikingly, our studies showed that CSN6 expres-
sion decreases the steady-state expression of b-Trcp. Because
Cullin neddylation, a process controlled by CSN, decreases the
steady-state expression levels of F-box proteins (Wee et al.,
2005), we rationalized that CSN6 may be involved in Cullin ned-
dylation, thereby increasing the autocatalytic degradation of
b-Trcp. Indeed, we recently showed that CSN6 is competing
with CSN5 for Cullin binding through its MPN domain (Chen
et al., 2014). Structurally, CSN6 and CSN5 form a heterodimer
through MPN domain, and the dimer is topologically knotted to
engage in Cullin deneddylation (Lingaraju et al., 2014). Reducing
CSN6 expression diminishes its competition with CSN5 in
terms of Cullin binding, thereby allowing CSN5 to mediate the
deneddylation of Cullin efficiently as observed in Csn6+/ ex-
tracts (Chen et al., 2014). On the other hand, it is conceivable
that in CSN6-overexpressing cancers abundant CSN6 binds
more amounts of Cullin and thus reduces the accessibility of
Cullin to CSN5 for deneddylation, thereby preserving Cullin
neddylation. More Cullin neddylation increases the autocatalytic
degradation of F-box protein such as Fbxw7 (Chen et al., 2014).
Here, we provided another example of CSN6-preserved Cullin
neddylation in affecting another F-box protein—b-Trcp and
showed how CSN6 can destabilize b-Trcp and subsequently
increase the stability of b-catenin.
In our study, cetuximab inhibited tumor growth in xenograft
colon cancer mice and prolonged their survival. Tumor sample
analysis indicated that cetuximab ablated the CSN6 and b-cate-
nin expression levels as well as ERK activation. Congruently,
CSN6 knockdown xenograft tumors had elevated b-Trcp and
diminished b-catenin expression and a slower growth rate.
Thus, these studies recapitulated the relationships among
EGF, ERK, CSN6, and b-catenin in vivo. Activating mutations
in KRAS, BRAF, and/or PIK3CA are well-known carcinogenic
mechanisms and may predict response to treatment of CRC
(Douillard et al., 2013; Mao et al., 2012; Nishihara et al., 2013;2 with GST-CSN6 and mutant GST-CSN6-S148A proteins. Cell lysates were
X (100 mg/ml) for the indicated times. Cell lysates were immunoblotted with the
d optical density (IOD) was measured. The turnover of Flag-CSN6 is indicated
lag-CSN6(S148D) and treated with EGF (100 ng/ml). MG132 was added to
he cell lysates were pulled down with nickel beads and immunoblotted with an
ates were measured by MTT assay. The results were measured at an optical
nd Flag-CSN6(S148D). Cell motility was analyzed by wound-healing assay,
resent three independent experiments. Data are means ± SD. **p < 0.01.
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Figure 4. CSN6 Increases b-Catenin Expression by Regulating Ubiquitination
(A) DLD-1 or SW480 cells were treated with EGF for the indicated times. Cell lysates were immunoblotted with the indicated antibodies.
(B) DLD-1 cells were transfected with increasing amounts of CSN6 plasmids. Cell lysates were immunoblotted with the indicated antibodies.
(C) DLD-1 cells were treated with shCSN6. Equal amounts of cell lysates were immunoblotted with the indicated antibodies.
(D) DLD-1 cells were treated with shCSN6. qRT-PCR analysis was performed to measure the mRNA levels of b-catenin–induced target genes. Data are
means ± SD.
(E) DLD-1 cells with control vector, WT-CSN6, or CSN6-S148A were transfected with either TOP-FLASH or FOP-FLASH (control vector). The relative luciferase
activity levels were normalized to those of control cells and the Renilla control plasmid. Data represent three independent experiments and are means ± SD.
**p < 0.01.
(legend continued on next page)
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Siena et al., 2009). It is known that human colon cancers bearing
mutatedKRAS do not respond to cetuximabwell, whereas those
bearing WT KRAS do respond to cetuximab (Karapetis et al.,
2008). Our previous data show that AKT signaling pathway
stabilizes CSN6 (Xue et al., 2012), and here we show that
RAS-MAPK pathway has a positive impact on CSN6 stability.
Because KRAS is an upstream regulator of these two pathways,
KRAS mutations will continue to activate both RAS-MAPK and
AKT pathways to stabilize CSN6, which in turn activates b-cate-
nin activity to cause pathogenesis in colon cancer. The worse
prognosis with EGFR antibody therapy (cetuximab) in colon
cancer cells/tumors harboring KRAS mutation can, at least in
part, be due to CSN6-b-catenin stabilization. CSN6 stabilization
and its downstream impact on b-catenin activation may lead
to cetuximab resistance. Thus CSN6’s expression level might
be used as a predictor for drug selection.
We also found that CSN6 overexpression is quite common
in CRC. Our cohort studies in Figure 1 indicate that CSN6 is
overexpressed in about 35%–80% of CRCs depending from
mRNA expression or tissue microarray studies. The deregulation
rate is comparable to other known markers. For example, Douil-
lard et al. (2013) show that RAS mutations (any KRAS or NRAS
mutations in exon 2, 3, or 4) in CRC could be about 52%,
whereas BRAF V660E mutation is found in 20% of colonic
tumors (Farin˜a-Sarasqueta et al., 2010; Pietrantonio et al.,
2015). CSN6 overexpression was positively correlated with
b-catenin protein expression and ERK activation in human
colon cancer samples. These findings demonstrate that CSN6
overexpression can at least partially account for b-catenin
overexpression in colon cancer and provide important insights
into the mechanisms underlying EGFR/ERK pathway deregula-
tion in colon cancer. That CSN6 acts as a positive regulator of
b-catenin raises the possibility that inhibiting the CSN6 signaling
axis is an efficient therapeutic approach in b-catenin-deregu-
lated colon cancer.
EXPERIMENTAL PROCEDURES
Detailed descriptions of the following procedures are provided in the Supple-
mental Experimental Procedures.
Patients and Tissue Samples
We obtained snap-frozen tissue samples from 20 CRC patients with stage III
disease who had undergone curative resection between 2007 and 2010 at
the Sixth Affiliated Hospital of Sun Yat-sen University. All patients received
adjuvant chemotherapy with modified FOLFOX6 (folinic acid, fluorouracil,
and oxaliplatin). Of the 20 patients, 7 had disease relapse within 3 years after
surgery.
Thirty-three fresh frozen paired samples of primary CRC and adjacent
normal colon tissue were collected from the Department of Surgery at the(F) DLD-1 cell lysates were immunoprecipitated with an anti-b-Trcp antibody and
(G) Cell lysates were prepared from DLD-1 cells expressing Flag-tagged WT CSN
lysates were immunoblotted with the indicated antibodies.
(H) DLD-1 cells were transfected with the indicated plasmids and treated with CH
indicated antibodies.
(I) DLD-1 cells were transfectedwith the indicated plasmids.MG132was added to
The cell lysates were pulled down with nickel beads and immunoblotted with the
(J) A heat map produced from transcriptomic analyses of CSN6 and b-catenin-
dataset was obtained from Oncomine and the Gene Expression Omnibus (cohor
See also Figure S3.Sixth Affiliated Hospital of Sun Yat-sen University. All patients had stage II or
stage III disease at the time of specimen collection.
We also obtained paraffin-embedded samples of primary colorectal adeno-
carcinomas from two independent CRC patient cohorts: (1) 81 patients from
the Sixth Affiliated Hospital of Sun Yat-sen University (the testing cohort)
and (2) 305 patients from the First Affiliated Hospital of Sun Yat-sen University
(the validation cohort). All samples were collected with the patients’ written
informed consent and approval from each study center’s Institutional Review
Board.
Microarray Analysis
RNA samples from 20 frozen CRC patient specimens were isolated using
the RiboPure Kit (Ambio). Gene expression profiles were determined using
Affymetrix HG-U133 Plus 2.0 GeneChips (Affymetrix) according to manu-
facturer’s instructions. Heat maps were generated using the Java Treeview
software program (http://jtreeview.sourceforge.net; used under general public
license).
Data Mining
CRC data sets were downloaded from the publicly available GEO databases
(290 patients from GEO14333 and 373 patients from GEO2109). GSEA was
performed by the JAVA program (http://www.broadinstitute.org/gsea) using
MSigDB C6.oncogenic signatures gene set collection and visualized in the
Enrichment Map software. b-Catenin target genes were selected according
to the Wnt home page (http://www.stanford.edu/group/nusselab/cgi-bin/
wnt/). The mRNA expression profiles of the CSN6, CSN5, and b-catenin target
genes in colon cancer tissuewere obtained by analyzing theOncomine Cancer
Microarray database (http://www.oncomine.org). The genes’ expression was
analyzed and visualized using Cluster and Treeview software (Eisen, MB)
and was presented as heat map as previously described (Fuentes-Mattei
et al., 2014).
Cell Lines
HCT116, DLD-1, and SW480 cells were obtained from ATCC. The HCEC cell
line was kindly provided by Dr. Shay (Roig et al., 2010). The AKP cell line
was kindly provided by Dr. Hung (Hung et al., 2010). Cells were maintained
in Dulbecco’smodified Eagle’s medium/nutrient F12media (in-house supplier)
supplemented with 10% (v/v) fetal bovine serum.
Transfection and Generation of Stable Transfectants
Standard protocols were used; details are given in the Supplemental Experi-
mental Procedures.
qPCR
TRIzol (Invitrogen) was used to extract total RNAs from cells or tissues. The
iScript cDNA Synthesis Kit (BioRad, #170-8891) was used to produce cDNA
from 1 mg of RNA. qRT-PCR was performed using a 7500 Real-Time PCR
System (Applied Biosystems) and SYBR Green PCR Master Mix (BioRad).
Primers for qRT-PCR of CSN6 and other genes are listed in Table S3. GAPDH
was used for normalization.
Western Blot Analysis and Immunoprecipitation
For western blot analysis, we used antibodies against Flag (M2 monoclonal
antibody, Sigma, #F3165), extracellular signal-regulated kinase (ERK)1/2
(Millipore, 06-182), p-ERK1/2 (Cell Signaling, #4370), p-serine (Cell Signaling,immunoblotted with the indicated antibodies.
6 that had been treated with or without MG132 for 8 hr. Equal amounts of cell
X (100 mg/ml) for the indicated times. Cell lysates were immunoblotted with the
the cells 6 hr before they were harvested with guanidine-HCl-containing buffer.
indicated antibodies.
induced target genes in 373 colon cancer patients. The human CRC patient
t GSE-2109).
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Figure 5. The pERK-CSN6-b-Catenin Axis Promotes Colon Cancer Growth in Mice and Cancer Patients
(A and B) DLD-1 cell were subcutaneously injected into nude mice (n = 4). Mice were treated with or without cetuximab. Tumor growth curves and representative
tumor sizes are shown. Data are the means ± SD.
(C) The tumors in (A) were isolated at the end of the assay, and tissue lysates were immunoblotted with the indicated antibodies.
(D and E) shCSN6-AKP colon cancer cells and control stable AKP colon cancer cells were subcutaneously injected into nude mice (n = 10). Tumor growth curves
are shown. The tumors were isolated at the end of the assay, and the tumor weight of each group wasmeasured. Representative tumor sizes are shown. Data are
means ± SD.
(F) Tumors in (D) were isolated at the end of the assay, and tissue lysates were immunoblotted with the indicated antibodies.
(G) Representative IHC staining for p-ERK, CSN6, and b-catenin in tumor tissues from mice. Scale bars represent 50 mm.
(legend continued on next page)
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#2325), b-catenin (BD, #610153), CSN6 (Biomol International, #PW8295),
b-Trcp (Cell Signaling, #4394), actin (Sigma, A2066), and Myc (sc-40, Santa
Cruz Biotechnology). Experimental details and primer sequences are given
in the Supplemental Experimental Procedures.
Ubiquitination Assay and Turnover Assay
Standard protocols were used as previously described (Choi et al., 2015; Gully
et al., 2012); details are given in the Supplemental Experimental Procedures.
Cell Proliferation Assay, Wound Healing Assay, and Migration
and Invasion Assay
Standard protocols were used; details are given in the Supplemental Experi-
mental Procedures.
Luciferase Reporter Gene Assay
The transcriptional activation of b-catenin in DLD-1 cells was measured as
described previously (Fang et al., 2007). Luciferase activity was assessed
with the dual luciferase assay system (Promega) according to the manufac-
turer’s instructions.
Xenograft Study
All animal work was conducted in accordance with American Association for
Laboratory Animal Science regulations and approval of The University of
Texas MD Anderson Cancer Center Institutional Animal Care & Use Commit-
tee. Male BALB/c nude mice, 4–6 weeks old, were obtained from The Univer-
sity of Texas MD Anderson Cancer Center. Mice were randomly divided into
experimental groups. Mice were injected subcutaneously with 4 3 106 DLD1
cells in a 50-ml volume using a 27-gauge needle. Five days after implantation,
the mice were assigned to the PBS-only or PBS plus cetuximab group. The
mice were treated three times per week with intraperitoneal injections of
1 mg of cetuximab in PBS or PBS alone.
For the shCSN6 study, mice were injected subcutaneously with 43 106 AKP
or shCSN6-AKP cells in a 50-ml volume using a 27-gauge needle. Tumor diam-
eters were serially measured with calipers three times each week, and tumor
volumes were calculated using the formula V = (LxW2)/2, where V = volume
(in mm3), L = length (in mm), andW = width (in mm). Total RNA was extracted
for qRT-PCR analysis. Sections of the harvested tissues were immunostained
with the indicated antibodies.
Statistical Analysis
Chi-square tests and one-way ANOVAwere used to assess differences in clin-
ical variables between the CRC cohorts. Kaplan-Meier survival analyses were
used to compare survival times among CRC patients based on CSN6 expres-
sion; the log-rank test was used to generate p values. Cox proportional haz-
ards regression analyses were used to assess the effect of clinical variables
on patient survival. Univariate and multivariate analysis were used to assess
the influence of clinical variables on survival. The p values and hazard ratios
are indicated. Differences between groups were evaluated using a two-tailed
t test or aMann-Whitney rank-sum test. All statistical analyses were performed
using SPSS 16.0. Paired samples were compared using a paired t test.ACCESSION NUMBERS
The Gene Expression Omnibus (GEO) accession number for the microarray
data reported in this paper is GEO: GSE60697.(H) RNA was extracted from tumor tissues. qRT-PCR analysis was performed
means ± SDs.
(I) Representative IHC staining for p-ERK, CSN6, and b-catenin in serial sections o
CSN6-overexpressing colon cancer. Case 2 is representative of a patient wit
305 colon cancer cases. Scale bars represent 50 mm.
(J) Model of ERK-induced CSN6 modulating b-catenin stability and tumorigenes
which in turn downregulates b-Trcp to preserve b-catenin, thereby facilitating tu
See also Figure S4 and Table S2.SUPPLEMENTAL INFORMATION
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